Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) Latest Company News

Oct 30, 2026, 10:23 UTC
Fosun Pharma repurchased 320,000 H shares on the Hong Kong Stock Exchange at HK$16.09–HK$16.50 per share for HK$5.2536 million, intending to hold them as treasury shares.
Source:
- finance.sina.cn
Oct 28, 2026, 09:24 UTC
Fosun Pharma repurchased 2 million H shares through the Hong Kong Stock Exchange at HK$16.36–HK$16.92 per share for HK$33.4126 million, to be held as treasury shares.
Source:
- finance.sina.cn
Oct 28, 2026, 05:44 UTC
Xuzhou Wanbang Jinqiao Pharmaceutical Co., Ltd. increased its registered capital from RMB 220 million to approximately RMB 490 million, an increase of about 121%.
Source:
- finance.sina.cn
Oct 27, 2026, 13:41 UTC
Fosun Pharma reported net profit attributable to shareholders of RMB2.667 billion for the nine months ended September 30, 2026, up 5.71% year over year, with basic earnings per share of RMB1.34.
Source:
- aastocks.com
Oct 27, 2026, 11:07 UTC
Fosun Pharma reported third-quarter 2026 revenue of RMB10.02 billion, up 1.44% year over year, net profit of RMB946 million, up 15.18%, and earnings per share of RMB0.36.
Source:
- aastocks.com
Oct 27, 2026, 11:07 UTC
Fosun Pharma reported first-nine-month 2026 revenue of RMB30.463 billion, up 3.64% year over year, net profit of RMB2.667 billion, up 5.71%, and earnings per share of RMB1.01.
Source:
- aastocks.com
Sep 30, 2026, 09:13 UTC
Fosun Pharma announced that its partially held Nanjing Fund will reduce capital by a total of RMB 434 million, with the group cutting its subscribed contribution by RMB 267 million, lowering the fund's total subscribed capital from RMB 797 million to RMB 363 million.
Source:
- finance.sina.cn
Sep 30, 2026, 09:11 UTC
Wenjie Zhang resigned as co-president of Fosun Pharma on September 30, 2026, for personal reasons, effective upon delivery of his resignation letter to the board.
Source:
- finance.sina.cn
- finance.sina.cn
Sep 23, 2026, 08:37 UTC
Shanghai Henlius Biotech, a controlling subsidiary of Fosun Pharma, signed a cooperation and license agreement with Amberstone on September 23, 2026, obtaining an exclusive global license to research, develop, manufacture and commercialize two products based on the T-MATE™ technology platform for agreed targets.
Source:
Sep 22, 2026, 09:48 UTC
Fosun Pharma repurchased 1.2 million H shares on the Hong Kong Stock Exchange on September 22, 2026 at HK$18.01–18.23 per share for a total of HK$21.7916 million, to be held as treasury shares.
Source:
- finance.sina.cn
Sep 21, 2026, 09:45 UTC
Shanghai Fosun Pharmaceutical (Group) repurchased 271,500 of its own shares on September 21, 2026 at prices between HK$17.78 and HK$17.98 per share for about HK$4.8623 million.
Source:
- aastocks.com
Sep 18, 2026, 09:08 UTC
Shanghai Fosun Pharmaceutical (Group) repurchased 1.3 million of its own shares on September 18 at HK$17.35–17.58 per share for about HK$22.77 million, bringing cumulative buybacks to 9.759 million shares, or 1.8% of issued shares.
Source:
- aastocks.com
Sep 17, 2026, 07:06 UTC
Shanghai Fuzhenkang Biotechnology Co., Ltd. was established, jointly held by Fosun Pharma's wholly owned subsidiary Fosun Diagnostics Technology (Shanghai) Co., Ltd. and other shareholders.
Source:
- finance.sina.cn
Sep 16, 2026, 10:11 UTC
Fosun Pharma repurchased 1.3 million of its own shares on the Hong Kong Stock Exchange on September 16, 2026 at HK$16.91–17.26 per share for a total of HK$22.2439 million, to be held as treasury shares.
Source:
- finance.sina.cn
- aastocks.com
Sep 8, 2026, 08:55 UTC
Fosun Pharma's controlling subsidiary received China's NMPA approval to conduct Phase II/III clinical trials for FXS5626 tablets to treat non-segmental vitiligo.
Source:
- finance.sina.cn
- aastocks.com
Sep 6, 2026, 08:55 UTC
Fosun Pharma's subsidiary will sell shares of Gland Pharma for approximately 294 million yuan.
Source:
Sep 4, 2026, 08:23 UTC
Fosun High Technology, the controlling shareholder of Fosun Pharma, pledged 330 million A-shares to ICBC Shanghai Changning Sub-branch on September 3, 2026, to secure debt repayment.
Source:
- finance.sina.cn
Sep 3, 2026, 10:01 UTC
China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.
Source:
Sep 3, 2026, 09:44 UTC
Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.
Source:
- finance.sina.cn
Sep 3, 2026, 08:20 UTC
Fosun Pharma's controlled subsidiary received regulatory approval from China's National Medical Products Administration for a new indication of its drug Luwometinib (brand name Fumaining) for adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type I.
Source:
- finance.sina.cn
- aastocks.com
Aug 27, 2026, 11:56 UTC
Fosun Pharma announced that its subsidiary Yaoyu Pharmaceutical's licensed-in drug Weiketuo (GR1803), a BCMA×CD3 bispecific antibody, received conditional approval from China's National Medical Products Administration for treating relapsed or refractory multiple myeloma in adults who have received at least three prior lines of therapy.
Source:
- finance.sina.cn
- aastocks.com
Aug 21, 2026, 02:35 UTC
Fosun Pharma announced that the first participant in the China Phase I clinical trial of its liver-targeted siRNA drug FXR0906 for hypertriglyceridemia has been dosed.
Source:
- aastocks.com
Aug 18, 2026, 20:30 UTC
Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.
Source:
- jordantimes.com
Aug 16, 2026, 23:48 UTC
Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.
Source:
Aug 13, 2026, 09:43 UTC
Fosun Pharma's controlled subsidiary initiated a Phase II clinical trial in China for FXS7553, a self-developed small-molecule oral DPP-1 inhibitor, to treat chronic obstructive pulmonary disease.
Source:
- aastocks.com
Jul 22, 2026, 08:23 UTC
Fosun Pharma's controlling shareholder Fosun High Technology released a pledge on 69 million A-shares on July 21, 2026, and disclosed a subsequent pledge plan.
Source:
- finance.sina.cn

Page 1Next →

600196.SH

Fosun Pharma repurchased 320,000 H shares on the Hong Kong Stock Exchange at HK$16.09–HK$16.50 per share for HK$5.2536 million, intending to hold them as treasury shares.

Fosun Pharma repurchased 2 million H shares through the Hong Kong Stock Exchange at HK$16.36–HK$16.92 per share for HK$33.4126 million, to be held as treasury shares.

Xuzhou Wanbang Jinqiao Pharmaceutical Co., Ltd. increased its registered capital from RMB 220 million to approximately RMB 490 million, an increase of about 121%.

Fosun Pharma reported net profit attributable to shareholders of RMB2.667 billion for the nine months ended September 30, 2026, up 5.71% year over year, with basic earnings per share of RMB1.34.

Fosun Pharma reported third-quarter 2026 revenue of RMB10.02 billion, up 1.44% year over year, net profit of RMB946 million, up 15.18%, and earnings per share of RMB0.36.

Fosun Pharma reported first-nine-month 2026 revenue of RMB30.463 billion, up 3.64% year over year, net profit of RMB2.667 billion, up 5.71%, and earnings per share of RMB1.01.

Fosun Pharma announced that its partially held Nanjing Fund will reduce capital by a total of RMB 434 million, with the group cutting its subscribed contribution by RMB 267 million, lowering the fund's total subscribed capital from RMB 797 million to RMB 363 million.

Wenjie Zhang resigned as co-president of Fosun Pharma on September 30, 2026, for personal reasons, effective upon delivery of his resignation letter to the board.

Fosun Pharma repurchased 1.2 million H shares on the Hong Kong Stock Exchange on September 22, 2026 at HK$18.01–18.23 per share for a total of HK$21.7916 million, to be held as treasury shares.

Shanghai Fosun Pharmaceutical (Group) repurchased 271,500 of its own shares on September 21, 2026 at prices between HK$17.78 and HK$17.98 per share for about HK$4.8623 million.

Shanghai Fosun Pharmaceutical (Group) repurchased 1.3 million of its own shares on September 18 at HK$17.35–17.58 per share for about HK$22.77 million, bringing cumulative buybacks to 9.759 million shares, or 1.8% of issued shares.

Shanghai Fuzhenkang Biotechnology Co., Ltd. was established, jointly held by Fosun Pharma's wholly owned subsidiary Fosun Diagnostics Technology (Shanghai) Co., Ltd. and other shareholders.

Fosun Pharma repurchased 1.3 million of its own shares on the Hong Kong Stock Exchange on September 16, 2026 at HK$16.91–17.26 per share for a total of HK$22.2439 million, to be held as treasury shares.

Fosun Pharma's controlling subsidiary received China's NMPA approval to conduct Phase II/III clinical trials for FXS5626 tablets to treat non-segmental vitiligo.

Fosun Pharma's subsidiary will sell shares of Gland Pharma for approximately 294 million yuan.

Fosun High Technology, the controlling shareholder of Fosun Pharma, pledged 330 million A-shares to ICBC Shanghai Changning Sub-branch on September 3, 2026, to secure debt repayment.

China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.

Fosun Pharma's controlled subsidiary received regulatory approval from China's National Medical Products Administration for a new indication of its drug Luwometinib (brand name Fumaining) for adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type I.

Fosun Pharma announced that the first participant in the China Phase I clinical trial of its liver-targeted siRNA drug FXR0906 for hypertriglyceridemia has been dosed.

Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.

Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.

Fosun Pharma's controlled subsidiary initiated a Phase II clinical trial in China for FXS7553, a self-developed small-molecule oral DPP-1 inhibitor, to treat chronic obstructive pulmonary disease.

Fosun Pharma's controlling shareholder Fosun High Technology released a pledge on 69 million A-shares on July 21, 2026, and disclosed a subsequent pledge plan.